Recibokibart

N/A

Report date: 2025/12/25 15:59:37

Base Information

Drug NameRecibokibart
Drug Alias NameRecombinant humanised anti-IL-36R monoclonal antibody (Huabo Biopharm)瑞西奇拜单抗又瑞派HB-0034
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Interleukin-36 receptor
TargetsInterleukin-36 receptor
Therapy Area/IndicationsGeneralised pustular psoriasisPsoriasisLupus Erythematosus, Systemic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Huaota Biopharmaceutical Co LtdZhejiang Huahai Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGeneralised pustular psoriasisLupus Erythematosus, SystemicColitis, Ulcerative
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A